Molecular detection methods of human papillomavirus (HPV)

International Journal of Biological Markers

Volumn 24, Issue 4, 2009, Pages 215-222

  Zaravinos, Apostolos ^a   Mammas, Ioannis N ^a   Sourvinos, George ^a   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

HPV; Hybridization; Molecular detection; PCR

Indexed keywords

VIRUS DNA;

ANALYTIC METHOD; DIRECT AMPLIFICATION ASSAY; DNA CONTENT; DNA EXTRACTION; DOT HYBRIDIZATION; HYBRID CAPTURE ASSAY; IN SITU HYBRIDIZATION; MOLECULAR GENETICS; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL AMPLIFIED HYBRIDIZATION; SOUTHERN BLOTTING; TARGET AMPLIFICATION ASSAY; VIRUS DETECTION; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 76649143076     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2010.754     Document Type: Review

References (88)

1. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73.
2. Swygart C. Human papillomavirus: disease and laboratory diagnosis. Br J Biomed Sci 1997; 54: 299-303.
3. Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus induced genetic cancer of the skin. Arch Dermatol 1995; 131: 1312-8.
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
5. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942-53.
6. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
7. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-85.
8. Sanclemente G, Gill DK. Human papillomavirus molecular biology and pathogenesis. J Eur Acad Dermatol Venereol 2002; 16: 231-40. 9. Fehrmann F, Laimins LA. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 2003; 22: 5201-7.
9. Mammas I, Sourvinos G, Giannoudis A, Spandidos DA. Human papilloma virus (HPV) and host cellular interactions. Pathol Oncol Res 2008; 14: 345-54.
10. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000; 92: 397-02.
11. Paraskevaidis E, Arbyn M, Sotiriadis A, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004; 30: 205-11.
12. Davies P, Arbyn M, Dillner J, et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 2006; 118: 791-6.
13. Kitchener HC, Almonte M, Wheeler P, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006; 95: 56-61.
14. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
15. Dokianakis DN, Sourvinos G, Sakkas S, et al. Detection of HPV and ras gene mutations in cervical smears from female genital lesions. Oncol Rep 1998; 5: 1195-8.
16. Sourvinos G, Rizos E, Spandidos DA. p53 Codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncol 2001; 37: 572-8.
17. Mammas IN, Zafiropoulos A, Sifakis S, et al. Human papillomavirus (HPV) typing in relation to ras oncogene mRNA expression in HPV-associated human squamous cervical neoplasia. Int J Biol Markers 2005; 20: 257-63.
18. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169: 235-40.
19. Tieben LM, ter Schegget J, Minnaar RP, et al. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 1993; 42: 265-79.
20. de Roda Husman AM, Walboomers JM, Hopman E, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. J Med Virol 1995; 46: 97-102.
21. de Roda Husman AM, Walboomers JM, van den Brule AJ, et al. The use of general primers GP5 and GP6 elongated at their 30 ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76: 1057-62.
22. Jacobs MV, Snijders PJ, van den Brule AJ, et al. A general primer GP5+/GP6(+)-mediated PCR enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35: 791-5.
23. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36: 3020-7.
24. Coutlee F, Hankins C, Lapointe N. Comparison between vaginal tampon and cervicovaginal lavage specimen collection for detection of human papillomavirus DNA by the polymerase chain reaction. The Canadian Women's HIV Study Group. J Med Virol 1997; 51: 42-7.
25. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357-61.
26. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998; 153: 1731-9.
27. Sasagawa T, Minemoto Y, Basha W, et al. A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV). Virus Res 2000; 67: 127-39.
28. Menzo S, Ciavattini A, Bagnarelli P, et al. Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiol 2008; 8: 112.
29. Meyer T, Arndt R, Stockfleth E, et al. Strategy for typing human papillomaviruses by RFLP analysis of PCR products and subsequent hybridization with a generic probe. Biotechniques 1995; 19: 632-9.
30. Kado S, Kawamata Y, Shino Y, et al. Detection of human papillomaviruses in cervical neoplasias using multiple sets of generic polymerase chain reaction primers. Gynecol Oncol 2001; 81: 47-52.
31. Lungu O, Wright TC Jr, Silverstein S. Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis. Mol Cell Probes 1992; 6: 145-52.
32. Wang TS, Chou HF, Liu WM, Choo KB. Semiautomated typing of human papillomaviruses by restriction fragment length polymorphism analysis of fluorescence-labeled PCR fragments. J Med Virol 1999; 59: 536-40.
33. Laconi S, Greco M, Pellegrini-Bettoli P, et al. One-step detection and genotyping of human papillomavirus in cervical samples by reverse hybridization. Diagn Mol Pathol 2001; 10: 200-6.
34. Jacobs MV, Snijders PJ, Voorhorst FJ, et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 1999; 52: 498-503.
35. Park TC, Kim CJ, Koh YM, et al. Human papillomavirus genotyping by the DNA chip in the cervical neoplasia DNA. Cell Biol 2004; 23: 119-25.
36. Grce M, Husnjak K, Skerlev M, Lipozencí J, Pavelić K. Detection and typing of human papillomaviruses by means of polymerase chain reaction and fragment length polymorphism in male genital lesions. Anticancer Res 2000; 20: 2097-102.
37. Kim CJ, Jeong JK, Park M, et al. HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions. Gynecol Oncol 2003; 89: 210-7.
38. Seo SS, Song YS, Kim JW, et al. Good correlation of HPV DNA test between selfcollected vaginal and clinician-collected cervical samples by the oligonucleotide microarray. Gynecol Oncol 2006; 102: 67-73.
39. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-42.
40. Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. J Clin Virol 2001; 22: 11-29.
41. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37: 2508-17.
42. Levi JE, Kleter B, Quint WGV, et al. High prevalence of human papillomavirus infections and high frequency of multiple genotypes in HIV-infected women in Brazil. J Clin Microbiol 2002; 40: 3341-5.
43. Gonçalves MA, Massad E, Burattini MN, Villa L. Relationship between human papillomavirus (HPV) genotyping and genital neoplasia in HIV-positive patients of Santos City, Sao Paulo. Brazil Int J STD Aids 1999; 10: 803-7.
44. Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol 1990; 215: 403-10.
45. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324: 17-27.
46. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-01.
47. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-94.
48. Roberts I, Ng G, Foster N, et al. Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR. BMC Biotechnol 2008; 8: 57.
49. Takács T, Jeney C, Kovács L, et al. Molecular beacon-based real-time PCR method for detection of 15 high-risk and 5 low-risk HPV types. J Virol Methods 2008; 149: 153-62.
50. de Araujo MR, De Marco L, Santos CF, et al. GP5+/6+ SYBR Green methodology for simultaneous screening and quantification of human papillomavirus. J Clin Virol 2009; 45: 90-5.
51. Hart KW, Williams OM, Thelwell N, et al. Novel method for detection, typing, and quantification of human papillomaviruses in clinical samples. J Clin Microbiol 2001; 39: 3204-12.
52. Lamarcq L, Deeds J, Ginzinger D, et al. Measurements of human papillomavirus transcripts by real time quantitative reverse transcription-polymerase chain reaction in samples collected for cervical cancer screening. J Mol Diagn 2002; 4: 97-102.
53. Wang-Johanning F, Lu DW, Wang Y, et al. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep papanicolaou tests using realtime polymerase chain reaction analysis. Cancer 2002; 94: 2199-10.
54. Cattani P, Siddu A, D'Onghia S, et al. RNA (E6/E7) versus DNA (E6/E7) assays for risk evaluation in women infected with human papillomavirus (HPV). J Clin Microbiol 2009; 47: 2136-41.
55. Kraus I, Molden T, Erno LE, et al. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer 2004; 90: 1407-13.
56. Lie AK, Risberg B, Delabie J, et al. DNA versus RNA based methods for HPV testing in screening evaluation of Hybrid Capture II and pre-tect HPV proofer in Norway 2004. In: Proceedings of the 21st International Papillomavirus Conference; 2004; 55.
57. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Cancer Res 1999; 59: 6132-6.
58. Melchers WJ, Herbrink P, Walboomers JM, et al. Optimization of human papillomavirus genotype detection in cervical scrapes by a modified filter in situ hybridization test. J Clin Microbiol 1989; 27: 106-10.
59. Ausubel FM. Short protocols in molecular biology: A compendium of methods from current protocols in molecular biology. 4th ed. New York, NY: Wiley, 1999.
60. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2001.
61. Caussy D, Orr W, Daya AD, et al. Evaluation of methods for detecting human papillomavirus deoxyribonucleotide sequences in clinical specimens. J Clin Microbiol 1988; 26: 236-43.
62. Guo M, Gong Y, Deavers M, et al. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol 2008; 46: 274-80.
63. Algeciras-Schimnich A, Policht F, Sitailo S, et al. Evaluation of quantity and staining pattern of human papillomavirus (HPV)-infected epithelial cells in thin-layer cervical specimens using optimized HPV-CARD assay. Cancer 2007; 111: 330-8.
64. Clavel C, Masure M, Putaud I, et al. Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. J Clin Pathol 1998; 51: 737-40.
65. Castle PE, Schiffman M, Burk RD, et al. Restricted crossreactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002; 11: 1394-9.
66. Hesselink AT, van den Brule AJ, Brink AA, et al. Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples. Cancer 2004; 102: 11-8.
67. Kornegay JR, Shepard AP, Hankins C, et al. Nonisotopic detection of human papillomavirus DNA in clinical specimens using a consensus PCR and a generic probe mix in an enzyme-linke immunosorbent assay format. J Clin Microbiol 2001; 39: 3530-6.
68. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 1066-71.
69. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening: a prospective study. Lancet 1999; 354: 20-5.
70. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201: 1-6.
71. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004; 73: 65-70.
72. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001; 358: 1782-3.
73. Perez C, Velasco J, Alonso J, et al. Comparison of the performance of two HPV DNA genotyping methods from paraffin-embedded cervical tissues. 23rd International Papillomavirus Conference and Clinical Workshop, Prague, 2006.
74. Giuliano AR, Papenfuss M, Abrahamsen M, et al. Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prev 2001; 10: 1129-36.
75. Richardson H, Abrahamowicz M, Tellier PP, et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005; 14: 1149-56.
76. Richardson H, Kelsall G, Tellier P, et al. The natural history of type specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003; 12: 485-90.
77. Schiffman M, Wheeler CM, Dasgupta A, et al. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am J Clin Pathol 2005; 124: 722-32.
78. Melchers WJ, Bakkers JM, Wang J, et al. Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad-spectrum of human papillomavirus types: clinical evaluation and follow-up. Am J Pathol 1999; 155: 1473-8.
79. Quint WG, Scholte G, van Doorn LJ, et al. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping. J Pathol 2001; 194: 154-8.
80. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357-61.
81. van Doorn LJ, Quint W, Kleter B, et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol 2002; 40: 979-83.
82. Castle PE, Gravitt PE, Solomon D, et al. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 2008; 46: 109-17.
83. Coutlee F, Gravitt PE, Richardson H, et al. The Canadian Women's HIV study group. Non-isotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. J Clin Microbiol 1999; 37: 1852-7.
84. Gravitt PE, Lacey JV, Brinton LA, et al. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev 2001; 10: 95-100.
85. Vernon SD, Unger ER, Williams D. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol 2000; 38: 651-5.
86. Lazcano-Ponce E, Herrero R, Munoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001; 91: 412-20.
87. van den Brule AJ, Pol R, Fransen-Daalmeijer N, et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 779-87.
88. Klaassen CH, Prinsen CF, de Valk HA, et al. DNA microarray format for detection and subtyping of human papillomavirus. J Clin Microbiol 2004; 42: 2152-60.